JP4629030B2 - 17−ハロゲン化19−ノルステロイド化合物の新製造方法及び中間体 - Google Patents
17−ハロゲン化19−ノルステロイド化合物の新製造方法及び中間体 Download PDFInfo
- Publication number
- JP4629030B2 JP4629030B2 JP2006505813A JP2006505813A JP4629030B2 JP 4629030 B2 JP4629030 B2 JP 4629030B2 JP 2006505813 A JP2006505813 A JP 2006505813A JP 2006505813 A JP2006505813 A JP 2006505813A JP 4629030 B2 JP4629030 B2 JP 4629030B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- group
- agent
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000000543 intermediate Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 49
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 125000000468 ketone group Chemical group 0.000 claims description 7
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 238000005658 halogenation reaction Methods 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000012351 deprotecting agent Substances 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 229930194542 Keto Natural products 0.000 claims description 3
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 238000005899 aromatization reaction Methods 0.000 claims description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 150000002902 organometallic compounds Chemical class 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- -1 furazolinyl Chemical group 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000010908 decantation Methods 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 description 1
- UWJLRUGVGBETRY-UHFFFAOYSA-N 1-(2-phenoxyethyl)piperidine;hydrobromide Chemical compound Br.C=1C=CC=CC=1OCCN1CCCCC1 UWJLRUGVGBETRY-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- DOJXGHGHTWFZHK-UHFFFAOYSA-N Hexachloroacetone Chemical compound ClC(Cl)(Cl)C(=O)C(Cl)(Cl)Cl DOJXGHGHTWFZHK-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Description
・ステロイド基質により工程数を削減することにより、
・精製を容易にさせるために合成の開始時に正にハロゲン化を実施することにより
最適にされた。
R1及びR2は、同一又は異なっていてよく、ベンジル基又は1〜8個の炭素原子を含有する線状の、分岐状の若しくは環状のアルキル、アルケニル若しくはアルキニル基を表わし、
或いは、R1及びR2は、これらを有する窒素原子と一緒になって、飽和又は不飽和の芳香族又は非芳香族の5又は6員の複素環(1〜3個の追加の複素原子を含有でき、また他の環に縮合していてもよい。)を形成し、
Xはハロゲン原子を表し、
R3は水素原子又はヒドロキシル官能基の保護基を表し、
nは2〜8の整数である。]
の化合物を製造するにあたり、
a)次式(II):
の化合物に17−位置のケトの還元剤を作用させて次式(III):
b)式(III)の化合物をハロゲン化剤で処理して次式(IV):
の化合物を得、
c)式(IV)の化合物にエポキシ化剤を作用させて次式(V):
d)式(V)の化合物に、触媒的に又は化学量論的に生じる、式R5MgHal又はR5Li(ここに、Halはハロゲン原子を表わし、R5は次式:
の基を表わす。)の有機金属化合物から誘導された有機銅酸塩(organocuprate)誘導体によるアルキル化反応に付し、結合はフェニル上で起こるようにし、
次いで脱保護剤を作用させて次式(VI):
e)式(VI)の化合物を芳香族化剤で処理して該式(I)の化合物を得、
f)要すれば、工程eで得られた化合物を脱保護反応に付して、R3が水素原子を表わす式(I)の化合物を得、要すれば、この化合物を塩形成反応及び中和反応に付する
工程を含む、式(I)の化合物の製造方法である。
・環状のケタール、例えば−O−(CH2)m−O−、−O−(CH2)m−S−、−S−(CH2)m−S−、−O−CH2−C(C1-4アルキル)2−CH2−O−、
・非環状のケタール、例えば(CH3O)2、(EtO)2、
・並びに当業者に知られた全てのケトの保護基、例えば、グリーン、ウッツ著「有機合成における保護基 第3版」(ウイリー&ソンズ社、1999)に記載されたもの。
ハロゲン化反応は、特に、弗化ペルフルオルブタンスルホニル、弗化水素酸/トリエチルアミン〔(HF)3・TEA〕錯体及びDBUの存在下に実施することができる。
・=Kが3,3−エチレンジオキシを表わす式(IV)の化合物、
・=Kが3,3−エチレンジオキシを表わす式(V)の化合物、
・Xが弗素原子を表し、nが2に等しく、且つ、R1及びR2がこれらを有する窒素原子と一緒になってそれらが次式:
・R3がアシル基を表し、Xが弗素原子を表し、nが2に等しく、且つ、R1及びR2がこれらを有する窒素原子と一緒になってそれらが次式:
・=Kが3,3−エチレンジオキシを表し、nが2に等しく、且つ、Xが弗素原子を表わす式(IV)の化合物、又は
・=Kが3,3−エチレンジオキシを表し、nが2に等しく、且つ、Xが弗素原子を表わす式(V)の化合物。
例1:11β−(4−(2−(1−ピペリジニル)エトキシ)フェニル)−17α−フルオルエストラ−1,3,5(10)−トリエン−3−オール
3,3−エチレンジオキシエストラ−5(10),9(11)− ジエン−17−オール
C20H28O3;MW=316.4。
IR(CHCl3、cm-1):ν3613、1638
1H NMR(CDCl3、ppm):δ0.74(s、3H);2.29(bs、2H);3.78(t、J=8.5Hz、1H);3.98(m、4H);5.57(m、1H);0.85〜2.6(m、16H)
3,3−エチレンジオキシ−17α−フルオルエストラ−5(10),9(11)−ジエン
IR(CHCl3、cm-1):ν1640、1610
1H NMR(CDCl3、ppm):δ0.66(d、J=2.5Hz、3H);3.99(bs、4H);4.59(dd、J=55及び5Hz、1H);5.60(m、1H);0.8〜2.6(m、18H)
MS(EI、m/z):318(M+);298(M+−HF)
3,3−エチレンジオキシ−17α−フルオル−5(10)−エポキシエストラ−9(11)−エン
IR(CHCl3、cm-1):ν1640
1H NMR(CDCl3、ppm):δ0.66(d、J=2.5Hz、3H);3.85〜3.97(m、4H);4.58(dd、J=55及び5Hz、1H);6.07(dt、J=5.5及び2.5Hz、1H);1.15〜2.57(m、18H)
17α−フルオル−11β−(4−(2−(1−ピペリジニル)エトキシ)フェニル)エストラ−4,9−ジエン−3−オン
IR(CHCl3、cm-1):1656、1608、1508
1H NMR(CDCl3、ppm):0.35(d、J=2Hz、3H);1.44(m、2H);1.60(m、4H);2.50(bt、J=6Hz、4H);2.76(t、J=6Hz、2H);4.07(t、J=6Hz、2H);4.39(m、1H);4.46(dd、J=55.5及び5Hz、1H);5.76(bs、1H);6.82及び7.07(AA’BB’、4H);1.2〜4.1(m、18H)
MS(EI、m/z):477(M+);457(M+−HF);366;346;98
3−アセチルオキシ−11β−(4−(2−(1−ピペリジニル)エトキシ)フェニル)−17α−フルオルエストラ−1,3,5(10)−トリエン
11β−(4−(2−(1−ピペリジニル)エトキシ)フェニル)−17α−フルオルエストラ−1,3,5(10)−トリエン−3−オール塩酸塩
IR(CHCl3、cm-1):ν=3599、2467、1609、1583、1511
1H NMR(CDCl3、ppm):0.22(d、J=1.5Hz、3H);3.09(m、1H);3.21(m、1H);3.87(m、1H);3.99(m、1H);4.25(m、1H);4.43(dd、J=56及び5Hz、1H);6.43及び6.95(AA’BB’、4H);6.60(dd、J=8.5及び1.5Hz、1H);6.67(d、J=1.5Hz、1H);6.78(d、J=8.5Hz、1H);11.4(bs、1H、活性);0.9〜3.4(m、14H)
MS(ESP、m/z):478(MH+)
11β−(4−(2−(1−ピペリジニル)エトキシ)フェニル)−17α−フルオルエストラ−1,3,5(10)−トリエン−3−オール
11β−(4−(2−(1−ピペリジニル)エトキシ)フェニル)−17α−フルオルエストラ−1,3,5(10)−トリエン−3−オール塩酸塩(28g;MW=514.1;54.5ミリモル)(工程f)をジクロルメタン(224mL)に加えてなる懸濁液に、炭酸ナトリウム(MW=106.0g;6.1g、1当量)の水溶液(112mL)を約20℃で導入する。この混合物を約20℃で30分間撹拌し、デカンテーションにより分離し、水洗する。有機相を硫酸ナトリウムで乾燥し、ろ過し、ろ液を140mLの残留容積まで濃縮する。20℃にもたらし、アセトン(280mL)を、次いでシリカ(メルクSi60;42g)を導入する。混合物を約20℃で1時間撹拌し、ろ過し、2/1のアセトン−ジクロルメタン混合物によりすすぎ洗いする。ろ液を224mLの最終容積が得られるまで濃縮する。次いで、これを、イソプロパノールを徐々に導入することにより容積を一定に保持しながら、常圧で蒸留する。生成物が連続的に結晶化する。媒体を冷却しながらほぼ1時間、次いで2時間で約0℃にもたらしながら撹拌する。生成物をろ過し、約0℃でイソプロパノールにより洗浄し、次いで約40℃で真空乾燥する。21.3gの白色の固体。Mp=180℃;収率82.1%;HPLC純度99%。C31H40FNO2;MW=477.7。
IR(CHCl3、cm-1):ν=3598、1610、1581、1512
1H NMR(CDCl3、ppm):0.16(d、J=2.5Hz、3H);1.34(m、2H);1.44(m、4H);2.37(m、4H);2.56(t、J=6Hz、2H);3.91(m、2H);3.95(m、1H);4.44(dd、J=56及び5Hz、1H);6.31(dd、J=8.5及び3Hz、1H);6.46(d、J=3Hz、1H);6.63及び6.97(AA’BB’、4H);6.71(d、J=8.5、1H);8.95(bs、1H、活性);0.9〜3.0(m、13H)
Claims (9)
- 次式(I):
R1及びR2は、同一又は異なっていてよく、ベンジル基又は1〜8個の炭素原子を含有する線状の、分岐状の若しくは環状のアルキル、アルケニル若しくはアルキニル基を表わし、
或いは、R1及びR2は、これらを有する窒素原子と一緒になって、飽和又は不飽和の芳香族又は非芳香族の5又は6員の複素環(1〜3個の追加の複素原子を含有でき、また他の環に縮合していてもよい。)を形成し、
Xはハロゲン原子を表し、
R3は水素原子又はヒドロキシル官能基の保護基を表し、
nは2〜8の整数である。]
の化合物を製造するにあたり、
a)次式(II):
の化合物に17−位置のケトの還元剤を作用させて次式(III):
b)式(III)の化合物をハロゲン化剤で処理して次式(IV):
の化合物を得、
c)式(IV)の化合物にエポキシ化剤を作用させて次式(V):
d)式(V)の化合物に、触媒的に又は化学量論的に生じる、式R5MgHal又はR5Li(ここに、Halはハロゲン原子を表わし、R5は次式:
の基を表わす。)の有機金属化合物から誘導された有機銅酸塩誘導体によるアルキル化反応に付し、結合はフェニル上で起こるようにし、
次いで脱保護剤を作用させて次式(VI):
e)式(VI)の化合物を芳香族化剤で処理して該式(I)の化合物を得、
f)要すれば、工程eで得られた化合物を脱保護反応に付して、R3が水素原子を表わす式(I)の化合物を得、要すれば、この化合物を塩形成反応及び中和反応に付する
工程を含む、式(I)の化合物の製造方法。 - =Kが環状のケタールを表わすことを特徴とする請求項1に記載の方法。
- Xが弗素原子を表わすことを特徴とする請求項1又は2に記載の方法。
- 17−ケトからアルコールへの還元がメタノール中で水素化硼素ナトリウムの作用によって行われることを特徴とする請求項1、2、3又は4に記載の方法。
- ハロゲン化反応が弗化水素酸/トリエチルアミン錯体及びジアザビシクロウンデセンの存在下に弗化ペルフルオルブタンスルホニルにより行われることを特徴とする請求項1、2、3又は4に記載の方法。
- 式(VI)の化合物を得るのに使用される脱保護剤が酸加水分解剤であることを特徴とする請求項1、2、3又は4に記載の方法。
- 芳香族化反応が臭化アセチル及び無水酢酸の存在下に行われることを特徴とする請求項1、2、3又は4に記載の方法。
- 請求項1に記載の方法に従って式(II)の化合物から式(IV)の化合物を製造するための方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0305222A FR2854403B1 (fr) | 2003-04-29 | 2003-04-29 | Nouveau procede et intermediaires de preparation de composes 19-nor-steroides 17-halogenes |
PCT/FR2004/001011 WO2004096829A2 (fr) | 2003-04-29 | 2004-04-27 | Nouveau procede et intermediaires de preparation de composes 19-nor-steroïdes-17-halogenes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006525290A JP2006525290A (ja) | 2006-11-09 |
JP4629030B2 true JP4629030B2 (ja) | 2011-02-09 |
Family
ID=33155513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006505813A Expired - Fee Related JP4629030B2 (ja) | 2003-04-29 | 2004-04-27 | 17−ハロゲン化19−ノルステロイド化合物の新製造方法及び中間体 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7449572B2 (ja) |
EP (1) | EP1622926B1 (ja) |
JP (1) | JP4629030B2 (ja) |
AR (1) | AR044103A1 (ja) |
AT (1) | ATE435869T1 (ja) |
CY (1) | CY1109434T1 (ja) |
DE (1) | DE602004021918D1 (ja) |
DK (1) | DK1622926T3 (ja) |
ES (1) | ES2328927T3 (ja) |
FR (1) | FR2854403B1 (ja) |
PL (1) | PL1622926T3 (ja) |
PT (1) | PT1622926E (ja) |
SI (1) | SI1622926T1 (ja) |
TW (1) | TW200510448A (ja) |
WO (1) | WO2004096829A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2854402B1 (fr) * | 2003-04-29 | 2008-07-04 | Aventis Pharma Sa | Nouveau procede et intermediaires de preparation de composes 19-nor-steroides |
HU227112B1 (hu) * | 2006-06-14 | 2010-07-28 | Richter Gedeon Nyrt | Ipari eljárás 17-alfa-acetoxi-11-béta-[4-(N,N-dimetil-amino)-fenil]-19-norpregna-4,9-dién-3,20-dion elõállítására és új intermedierek az eljáráshoz |
CN105979780A (zh) | 2013-12-11 | 2016-09-28 | 斯隆-凯特林癌症研究院 | 治疗前列腺癌的糖皮质激素抑制剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3264327A (en) * | 1962-07-27 | 1966-08-02 | Syntex Corp | 17alpha-fluoro-, 17beta-chlorofluoroacetoxy- and 17beta-methyl-delta4-and delta5-androstene derivatives |
FR2528434B1 (fr) * | 1982-06-11 | 1985-07-19 | Roussel Uclaf | Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament |
FR2640977A2 (en) * | 1982-06-11 | 1990-06-29 | Roussel Uclaf | New position-11 substituted 19-norsteroids and their application as medicinal products. |
FR2771096B1 (fr) * | 1997-11-17 | 2000-08-11 | Hoechst Marion Roussel Inc | Nouveaux 19-nor steroides, substitues en position 11beta, procede et intermediaires de preparation, application comme medicaments et compositions pharmaceutiques les renfermant |
FR2780060B1 (fr) * | 1998-06-23 | 2000-08-04 | Hoechst Marion Roussel Inc | Nouveaux 19-nor steroides 17-halogenes, procede et intermediaires de preparation, application comme medicaments et compositions pharmaceutiques les renfermant |
FR2854402B1 (fr) * | 2003-04-29 | 2008-07-04 | Aventis Pharma Sa | Nouveau procede et intermediaires de preparation de composes 19-nor-steroides |
-
2003
- 2003-04-29 FR FR0305222A patent/FR2854403B1/fr not_active Expired - Fee Related
-
2004
- 2004-04-27 DE DE602004021918T patent/DE602004021918D1/de not_active Expired - Lifetime
- 2004-04-27 DK DK04742578T patent/DK1622926T3/da active
- 2004-04-27 AR ARP040101423A patent/AR044103A1/es unknown
- 2004-04-27 SI SI200431231T patent/SI1622926T1/sl unknown
- 2004-04-27 ES ES04742578T patent/ES2328927T3/es not_active Expired - Lifetime
- 2004-04-27 PT PT04742578T patent/PT1622926E/pt unknown
- 2004-04-27 AT AT04742578T patent/ATE435869T1/de active
- 2004-04-27 JP JP2006505813A patent/JP4629030B2/ja not_active Expired - Fee Related
- 2004-04-27 WO PCT/FR2004/001011 patent/WO2004096829A2/fr active Application Filing
- 2004-04-27 PL PL04742578T patent/PL1622926T3/pl unknown
- 2004-04-27 EP EP04742578A patent/EP1622926B1/fr not_active Expired - Lifetime
- 2004-04-28 TW TW093111817A patent/TW200510448A/zh unknown
- 2004-04-29 US US10/834,638 patent/US7449572B2/en active Active
-
2009
- 2009-09-24 CY CY20091100992T patent/CY1109434T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7449572B2 (en) | 2008-11-11 |
TW200510448A (en) | 2005-03-16 |
EP1622926B1 (fr) | 2009-07-08 |
ATE435869T1 (de) | 2009-07-15 |
FR2854403B1 (fr) | 2008-07-11 |
EP1622926A2 (fr) | 2006-02-08 |
SI1622926T1 (sl) | 2009-12-31 |
PL1622926T3 (pl) | 2009-12-31 |
JP2006525290A (ja) | 2006-11-09 |
PT1622926E (pt) | 2009-09-07 |
DE602004021918D1 (de) | 2009-08-20 |
US20040224933A1 (en) | 2004-11-11 |
CY1109434T1 (el) | 2014-08-13 |
WO2004096829A2 (fr) | 2004-11-11 |
FR2854403A1 (fr) | 2004-11-05 |
ES2328927T3 (es) | 2009-11-19 |
WO2004096829A3 (fr) | 2005-02-03 |
DK1622926T3 (da) | 2009-11-16 |
AR044103A1 (es) | 2005-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3984315B2 (ja) | ステロイド誘導体のケタールの製造方法 | |
US8258328B2 (en) | Method and intermediates for preparing 19-norsteroid compounds | |
JP5430603B2 (ja) | ググルステロン及びググルステロールの製造方法 | |
JP4629030B2 (ja) | 17−ハロゲン化19−ノルステロイド化合物の新製造方法及び中間体 | |
US5502044A (en) | Fluorinated 4-aminoandrostadienone derivatives and process for their preparation | |
JP7419302B2 (ja) | 11-メチレンステロイドの製造のための方法および新規な中間体 | |
JP5250174B2 (ja) | 7α−メチルステロイドの調製方法 | |
JP2004534796A (ja) | エストロゲン誘導体の製造方法 | |
JP4263478B2 (ja) | 4−(17α−置換−3−オキソエストラ−4,9−ジエン−11β−イル)ベンズアルデヒド−(1Eまたは1Z)−オキシムの製造法 | |
JPH0592988A (ja) | ステロイド中間体化合物 | |
US20060111332A1 (en) | Process and intermediates to prepare17beta-hydroxy-7alpha-methyl-19-nor-17alpha-pregn -5(10)-en-20-yn-3-one | |
JPH0565294A (ja) | 20−イソシアノ−20−スルホニル−デルタ16−ステロイド及びその製造方法 | |
JP2004513178A (ja) | 4−(17α−メチル−置換3−オキソエストラ−4,9−ジエン−11β−イル)ベンズアルデヒド−(1Eまたは1Z)−オキシム | |
EP3655419A1 (en) | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof | |
TW201109346A (en) | Substituted 16,17-annellated steroid compounds for use in women's healthcare |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101012 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101110 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131119 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4629030 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |